Paper Details

  1. Home
  2. Paper Details

Treatment of recurrent herpes simplex labialis with oral acyclovir.

Author: FreemanD J, McKeoughM B, RoweN H, SpruanceS L, StewartJ C, WenerstromG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

Acyclovir (400 mg five times daily for 5 days) was more effective than placebo in reducing the frequency of positive herpes simplex labialis cultures. Acyclovir also hastened lesion resolution when started early in the prodrome or erythema stage.
Paper Details　
Original Abstract of the Article :
In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment start...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1093/infdis/161.2.185

データ提供：米国国立医学図書館（NLM）

Oral Acyclovir: A Powerful Tool Against Herpes Simplex Labialis

The field of virology is constantly striving to understand and combat viral infections. This double-blind, randomized, patient-initiated clinical trial investigates the effectiveness of oral acyclovir in treating recurrent herpes simplex labialis, a common and often bothersome condition. The authors compared the efficacy of acyclovir capsules with placebo capsules in 174 patients with a history of virus-culture-confirmed herpes simplex labialis. Their findings reveal that oral acyclovir significantly reduces the frequency of positive lesion virus cultures and can hasten lesion resolution, offering a valuable treatment option for individuals struggling with recurrent herpes simplex labialis.

A Beacon of Hope in the Desert of Herpes Simplex Labialis

This study demonstrates the effectiveness of oral acyclovir in treating recurrent herpes simplex labialis. The drug's ability to reduce the frequency of positive lesion virus cultures and accelerate lesion resolution is a significant finding for individuals seeking relief from this condition. This research offers hope for those battling recurrent herpes simplex labialis, a common and often challenging condition. It is a reminder that the desert of viral infections is vast and complex, but with research and innovation, we can find effective treatments to improve the health and well-being of patients.

Navigating the Desert of Viral Infections

This study highlights the importance of developing effective treatments for viral infections. Oral acyclovir's efficacy in treating recurrent herpes simplex labialis offers a valuable tool for managing this common condition. This research underscores the importance of ongoing research to develop new and effective antiviral therapies. It's a reminder that the desert of viral infections is vast and complex, but with continuous innovation, we can find better ways to combat these threats to human health.

Dr.Camel's Conclusion

This clinical trial provides compelling evidence for the effectiveness of oral acyclovir in treating recurrent herpes simplex labialis. The drug's ability to reduce viral shedding and accelerate lesion resolution offers a valuable treatment option for patients. This research is a testament to the ongoing efforts to develop effective treatments for viral infections, a journey through the vast desert of virology.

Date :
  1. Date Completed 1990-03-09
  2. Date Revised 2019-05-10
Further Info :

Pubmed ID

2153735

DOI: Digital Object Identifier

10.1093/infdis/161.2.185

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.